GSK is paying $66 million upfront to license rights to Spero Therapeutics novel antibiotic tebipenem Hbr, unswayed by the FDA's decision earlier this year not to approve the drug for adults with ...
Instead of revising his effort to muzzle school districts, Callender should just kill HB 671: editorial School districts not only have the right but also, one can reasonably argue, the duty to protect ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results